Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01339559 · ClinicalTrials.gov registry record · Phase 3
Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy
A Phase 3 study of Epilepsy, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 767
- Enrollment target
- 20
- Study locations
NCT01339559: Completed Phase 3 study of Epilepsy, sponsored by UCB Biosciences.
NCT01339559 is a Phase 3 study of Epilepsy that has completed, run by UCB Biosciences. The registered enrollment target is 767 participants, below the 948-participant average among 160 other Epilepsy trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01339559, a Phase 3 study of Epilepsy, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 767 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).
Primary Outcome
Treatment-emergent Adverse Events (TEAEs) were defined as those events which started on or after the date of first dose of investigational medicinal product (IMP), or events in which severity worsened on or after the date of first dose of study medication. The event does not necessarily have a causal relationship with that treatment or usage.
Conditions Studied
Interventions
- DRUG Brivaracetam
Study Locations (20)
Arizona
- 001 - Phoenix
- 013 - Phoenix
- 006 - Tucson
Florida
- 071 - Miami
- 027 - Orlando
- 064 - Port Charlotte
Illinois
- 029 - Chicago
- 005 - Peoria
- 017 - Winfield
Georgia
- 023 - Atlanta
- 048 - Rome
Iowa
- 020 - Ames
- 069 - Iowa City
Maryland
- 008 - Bethesda
- 068 - Waldorf
Arkansas
- 775 - Little Rock
California
- 025 - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 767 participants |
| Start Date | 2011-05-11 |
| Est. Completion | 2019-04-18 |
| Phase | Phase 3 |
What the finished NCT01339559 record still lists
NCT01339559 is an interventional study that assigns participants to a tested intervention. The registered 767 participants enrollment target is mid-sized for trials with a published cap, below the 948-participant average among 160 other Epilepsy trials with a reported enrollment target (19% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Brivaracetam is the first listed.
NCT01339559 names 20 study sites across 11 states, led by Arizona, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT01339559 about?
NCT01339559 is a clinical study titled "Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy". This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).
What is the current status of trial NCT01339559?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 767 participants. The study started on 2011-05-11. Estimated completion is 2019-04-18.
What conditions does trial NCT01339559 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT01339559?
The interventions under investigation include: Brivaracetam (DRUG).
Who is sponsoring clinical trial NCT01339559?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01339559 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01339559's enrollment target sits among peer trials
767 8th of 160 higher than 153 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
RECRUITING · Phase 3
-
Lemborexant Treatment of Insomnia Linked to Epilepsy
RECRUITING · Phase 3
-
RNS System NAUTILUS Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
COMPLETED · Phase 3
-
Clobazam in Patients With Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
Pediatric Epilepsy Study
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05119556 · 768 participants · NA
Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease
- NCT05404750 · 768 participants
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
- NCT05660525 · 768 participants · NA
Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia
- NCT06324357 · 768 participants · Phase 1
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI